Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accera Sees New Potential As It Renames, Expands To Asia To Progress Alzheimer’s Asset

Executive Summary

The US bioventure Accera, hit by a Phase III failure for its lead candidate last year, is expanding into Asia and renaming itself as it remains hopeful of progressing its core investigational asset in a targeted population of Alzheimer’s disease patients.

You may also be interested in...



Asia Executives On The Move: Senior Changes At Biogen, Amicus, PhRMA In Japan, Ascletis and Lupin

The coming of autumn ushers in a flurry of executive changes. Biogen has a new R&D head for Japan while Amicus Japan has a  new president, and other executive changes take place at Ascletis, Lupin and industry trade groups PhRMA and IPA.

Eisai/Biogen Remain In BACE Race As Alzheimer's Contenders Dwindle

Multiple competitors have ended development of BACE inhibitors for the treatment of Alzheimer's disease, but Eisai neurology executive Lynn Kramer tells Scrip that the company still sees a path forward for certain amyloid-targeting drugs.

Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel